title: [Etanercept and neoplasms].
abstract: The introduction of tumor necrosis factor (TNF) beta blockers has make it possible to obtain a significant advance in the control and knowledge of some inflammatory diseases, among them psoriasis. TNF is a cytokine that plays a key role in the control of infections and neoplasms. The increase of the risk of developing a neoplasm during the use of this group of drugs is one of the more debated adverse effects in the literature. We present the clinical case of one patient with long-course psoriasis who developed a breast adenocarcinoma after initiating treatment with etanercept. In this article, we provide a brief review on the possible associations existing between the use of anti-TNF therapy and the risk of the appearance of come neoplasms, among which leukemias, lymphomas and some solid tumors stand out.
authors.affiliation: Servicio de Dermatología, Consorcio Hospital General Universitario, Valencia, España. anagrabasco@gmail.com
authors.forename: A
authors.initials: A
authors.lastname: García-Rabasco
authors.forename: J L
authors.initials: JL
authors.lastname: Sánchez-Carazo
authors.forename: A
authors.initials: A
authors.lastname: Esteve
mesh_terms: D000230:Adenocarcinoma / Q000139:chemically induced*; D000328:Adult; D001943:Breast Neoplasms / Q000139:chemically induced*; D003663:Decision Trees; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D011565:Psoriasis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept